Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01212
|
|||||
| Drug Name |
Mitomycin
|
|||||
| Synonyms |
Ametycin; 1950/7/7; 7-Amino-9alpha-methoxymitosane; Ametycin; Ametycine; C15H18N4O5; CCRIS 414; EINECS 200-008-6; HSDB 3239; MMC; Mit-C; Mitamycin; Mito-C; Mitocin C; Mitocin-C; Mitomicina; Mitomicina [INN-Spanish]; Mitomycin (TN); Mitomycin (USP/INN); Mitomycin C; Mitomycin C (JP15); Mitomycin C from Streptomyces caespitosus; Mitomycin C,; Mitomycin C, Streptomyces caespitosus; Mitomycin C, Streptomyces caespitosus, Carrier-Free; Mitomycin [USAN:INN:BAN]; Mitomycin-C; Mitomycine; Mitomycine [INN-French]; Mitomycins; Mitomycinum; Mitomycinum C; Mitomycinum [INN-Latin]; Mitomycyna C; Mitomycyna C [Polish]; Mitosol; Mitozytrex; Muamycin; Muamycin (TN); Mutamycin; Mytomycin; Mytozytrex; NCI-C04706; NSC 26980; NSC-26980; NSC26980; RCRA waste number U010; UNII-50SG953SK6; mitomycin C
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Anxiety [ICD11:MB24.3] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H18N4O5
|
|||||
| Canonical SMILES |
CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3(C2COC(=O)N)OC)N4)N
|
|||||
| InChI |
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
|||||
| InChIKey |
NWIBSHFKIJFRCO-WUDYKRTCSA-N
|
|||||
| CAS Number |
CAS 50-07-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 334.33 | Topological Polar Surface Area | 147 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-0.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11120094
,11120582
,11121070
,11121809
,11122289
,11147177
,11363021
,11365583
,11368145
,11371173
,11371174
,11373746
,11376307
,14899962
,14924490
,15249200
,24896554
,24896555
,24896917
,26759169
,26759192
,29224783
,46508353
,47440503
,47440504
,47589205
,48414068
,48416286
,48423722
,49854359
,50064401
,50111457
,53787087
,56310827
,56311910
,56312869
,56312950
,56313687
,56313798
,56313799
,56314173
,56314310
,57260126
,57322926
,613813
,7847275
,8144500
,8153525
,87663
,8906
|
|||||
| ChEBI ID |
ChEBI:27504
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Mitomycin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.